ArticleNature biotechnology2026
Growth-coupled microbial biosynthesis of the animal pigment xanthommatin.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Discovery of the 5-Chlorokynurenine Pathway in Lodopyridone Biosynthesis.Journal of natural products · 2026Article
- Cascading recombinase memory switch for programmable and stable gene expression in Pseudomonas putida.Nucleic acids research · 2026Article
- Systems metabolic engineering for hydroxytyrosol production inApplied and environmental microbiology · 2026Article
- Break it to make it: Rewiring bacterial metabolism for the growth-coupled biosynthesis of xanthommatin animal pigments.Chem catalysis · 2026Article
- Engineering yeast for sustainable bioproduction of tryptophan-derived aromatic compounds.FEMS yeast research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Engineering heterologous natural product pathways in bacteria has achieved broad success but most approaches suffer from low initial production levels that require extensive, resource-heavy iterative strain optimization. Xanthommatin is a structurally complex, color-changing animal ommochrome with material and cosmetic applications, yet production in microbial cell factories has been difficult. Here, we introduce a growth-coupled biosynthetic strategy involving a feedback loop where an excised one-carbon (C1) moiety is used as a driver of bacterial growth, simultaneously boosting bioproduction of the target compound. This broadly applicable, plug-and-play strategy is illustrated by enabling xanthommatin biosynthesis in a 5,10-methylenetetrahydrofolate auxotroph of the platform soil bacterium Pseudomonas putida. In this design, formate released during xanthommatin production relieves the C1 deficiency, thereby effectively coupling bacterial growth to pigment synthesis. Adaptive laboratory evolution streamlined xanthommatin's gram-scale bioproduction from glucose, establishing C1 restoration as a general biosynthetic approach to accelerate the engineering of natural product biosynthesis in bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.